Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.
As of close of business last night, Crinetics Pharmaceuticals Inc’s stock clocked out at $36.53, down -1.22% from its previous closing price of $36.98. In other words, the price has decreased by -$1.22 from its previous closing price. On the day, 0.7 million shares were traded. CRNX stock price reached its highest trading level at $37.535 during the session, while it also had its lowest trading level at $36.48.
Ratios:
To gain a deeper understanding of CRNX’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 16.38 and its Current Ratio is at 16.38. In the meantime, Its Debt-to-Equity ratio is 0.06 whereas as Long-Term Debt/Eq ratio is at 0.05.
On January 22, 2025, Jefferies Upgraded its rating to Buy which previously was Hold but kept the price unchanged to $55.
On March 06, 2024, Citigroup started tracking the stock assigning a Buy rating and target price of $68.Citigroup initiated its Buy rating on March 06, 2024, with a $68 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Feb 03 ’25 when Pizzuti Dana sold 5,000 shares for $39.07 per share. The transaction valued at 195,350 led to the insider holds 31,748 shares of the business.
DANA J PIZZUTI bought 5,000 shares of CRNX for $195,372 on Feb 03 ’25. On Jan 03 ’25, another insider, Pizzuti Dana, who serves as the Chief Med and Dev Officer of the company, sold 15,000 shares for $52.09 each. As a result, the insider received 781,350 and left with 29,248 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CRNX now has a Market Capitalization of 3429436160 and an Enterprise Value of 2577576448. Its current Enterprise Value per Revenue stands at 2480.824 whereas that against EBITDA is -8.465.
Stock Price History:
The Beta on a monthly basis for CRNX is 0.57, which has changed by 0.027507663 over the last 52 weeks, in comparison to a change of 0.21659255 over the same period for the S&P500. Over the past 52 weeks, CRNX has reached a high of $62.53, while it has fallen to a 52-week low of $35.51. The 50-Day Moving Average of the stock is -23.51%, while the 200-Day Moving Average is calculated to be -27.53%.
Shares Statistics:
It appears that CRNX traded 847.95K shares on average per day over the past three months and 782160 shares per day over the past ten days. A total of 92.74M shares are outstanding, with a floating share count of 86.88M. Insiders hold about 6.31% of the company’s shares, while institutions hold 93.13% stake in the company. Shares short for CRNX as of 1736899200 were 7169914 with a Short Ratio of 8.46, compared to 1734048000 on 6252651. Therefore, it implies a Short% of Shares Outstanding of 7169914 and a Short% of Float of 7.870000000000001.
